Literature DB >> 34165671

Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes.

Olakunle Sanni1, G Terre'Blanche2.   

Abstract

Type 2 diabetes has been a global health challenge over the decades and is among the leading causes of death. Several treatment approaches have been developed, but more effective and new therapies are still needed. The role of adenosine in glucose and lipid homeostasis has offered a different therapeutic approach. Adenosine mediates its physiological role through the activation of adenosine receptors. These adenosine receptors have been implicated in glucose and lipid homeostasis. The ability of agonists and antagonists of adenosine receptors to activate or inhibit the adenosine signalling cascade and thereby affecting the balance of glucose and lipid homeostasis has challenged the studies of agonists and antagonists of adenosine receptors, both preclinical and clinical, as potential anti-diabetic drugs. This review provides a background on different anti-diabetic therapeutic approaches, outlining the role of adenosine receptors in glucose and lipid homeostasis, and mechanisms underlying the action of agonists/antagonists of adenosine receptors as a therapeutic potential towards type 2 diabetes.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adenosine receptors; Agonist and antagonist; Glucose homeostasis; Type 2 diabetes

Mesh:

Substances:

Year:  2021        PMID: 34165671     DOI: 10.1007/s11154-021-09668-8

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  119 in total

1.  Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study.

Authors:  D M Nathan
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 2.  Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations.

Authors:  Luca Antonioli; Corrado Blandizzi; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

3.  Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.

Authors:  A Mitrakou; D Kelley; T Veneman; T Jenssen; T Pangburn; J Reilly; J Gerich
Journal:  Diabetes       Date:  1990-11       Impact factor: 9.461

Review 4.  Autoregulation of hepatic glucose production.

Authors:  M C Moore; C C Connolly; A D Cherrington
Journal:  Eur J Endocrinol       Date:  1998-03       Impact factor: 6.664

Review 5.  Targeting the pancreatic β-cell to treat diabetes.

Authors:  Amedeo Vetere; Amit Choudhary; Sean M Burns; Bridget K Wagner
Journal:  Nat Rev Drug Discov       Date:  2014-02-14       Impact factor: 84.694

6.  Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia.

Authors:  Rita Basu; Cristina Barosa; John Jones; Simmi Dube; Rickey Carter; Ananda Basu; Robert A Rizza
Journal:  J Clin Endocrinol Metab       Date:  2013-01-23       Impact factor: 5.958

7.  Adenosine signaling contributes to ethanol-induced fatty liver in mice.

Authors:  Zhongsheng Peng; Pier Andrea Borea; Katia Varani; Tuere Wilder; Herman Yee; Luis Chiriboga; Michael R Blackburn; Gianfranco Azzena; Giuseppe Resta; Bruce N Cronstein
Journal:  J Clin Invest       Date:  2009-02-16       Impact factor: 14.808

8.  Insulin resistance of protein metabolism in type 2 diabetes.

Authors:  Sandra Pereira; Errol B Marliss; José A Morais; Stéphanie Chevalier; Réjeanne Gougeon
Journal:  Diabetes       Date:  2007-10-16       Impact factor: 9.461

9.  Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production.

Authors:  A Christine Könner; Ruth Janoschek; Leona Plum; Sabine D Jordan; Eva Rother; Xiaosong Ma; Chun Xu; Pablo Enriori; Brigitte Hampel; Gregory S Barsh; C Ronald Kahn; Michael A Cowley; Frances M Ashcroft; Jens C Brüning
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

Review 10.  Insulin as a physiological modulator of glucagon secretion.

Authors:  Pritpal Bansal; Qinghua Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-22       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.